Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies. (15th December 2016) - Prebet, Thomas; Delaunay, Jacques; Wattel, Eric; Braun, Thorsten; Cony‐Makhoul, Pascale; Dimicoli, Sophie; Wickenhauser, Stephan; Lejeune, Julie; Chevret, Sylvie; Chermat, Fatiha; Fenaux, Pierre; Vey, Norbert; et al.